ACE2 and COVID-19: Arguably, Baricitinib should disrupt ACE2-mediated SARS-CoV-2 endocytosis entry into cells within the same therapeutic plasma concentration range when used for rheumatoid arthritis; therefore, Baricitinib is postulated to be another candidate for clinical trials to treat COVID-19 [120,144,145].